Technical Data
Hepcidin, CT, 13aa (Hepc, LEAP, Hepatic Bactericidal Protein, Liver Expressed Antimicrobial Peptide)
Hepcidin (Hepc, hepatic bactericidal protein) or LEAP (liver expressed antimicrobial peptide) is a small, cysteine-rich peptide, antimicrobial peptide similar to defensins and thionins. Hepcidin (unprocessed, proprotein in mouse 83aa, rat/human 84aa) are almost exclusively produced in liver. Human hepcidin is produced from an 84aa precursor, including a putative 24aa signal peptide. The secreted form of hepcidin in blood and urine is consists of C-terminal 20, 22 or 25aa residues. The link between hepcidins and iron metabolism is that hepcidin expression is abolished in mice exhibiting iron-overload due to the targeted disruption of USF2 (upstream stimulatory factor 2) gene resembling the situation in hfe-/- mice. The human gene is located at chromosome 19, in close proximity with Usf2 gene. Hepcidin levels are increased in iron loading and in beta-2 microglobulin knockout mice. Hepcidins are devoid of IRE. Like other antimicrobial peptides, hepcidin is upregulated by lipopolysaccharides (LPS).

Suitable for use in ELISA. Other applications not tested.

Recommended Dilutions:
ELISA: 1:100,000. Using 50-100ng control peptide/well.
Optimal dilutions to be determined by the researcher.

Recommended Control Peptide:
H2008-55: Hepcidin, Mouse, 13aa, CT, Control Peptide

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
50ug-20CBlue IceMouseRabbit
Synthetic peptide corresponding to13aa within the C-terminus of mature mouse HEPC. Species Sequence Homology: rat, 92%; human, 69% (20-, 22- and 25-aa C-terminal fragments).
Purified by immunoaffinity chromatography.
Supplied as a liquid in PBS, 0.1% BSA.
Recognizes mouse Hepcidin. May react with the unprocessed larger 60aa pro-HEPC.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Peyssonnaux, C., Blood 107: 3727-3732 (2006) - IF. 2. Peyssonnaux, C., J. Clin. Invest. 117: 1926-1932 (2007) - IHC. 3. Duvigneau, J.C., et al., Lab. Invest. 88: 70-77 (2007). 4. Dallalio, G., 2003, British J. Haematol. 122: 996-1000 (2003), WB. 3. Peyssonnaux, C., J. Clin. Invest. 117: 1926 (2007), IHC. 5. Sow, F.B., J. Leukoc. Biol. 82: 934-945 (2007), WB. 6. Peyssonnaux, C., Blood, 107: 3727-3732 (2006) WB, IF. 7. Huang, Y-S., 2006, Pediatr. Res. May 2006; 59: 662-666 (2006), IHC. 8. Pigeon, C., et al., JBC 276: 7811-7819 (2001). 9. Park, C.H., et al., JBC 276: 7806-7810 (2001). 10. Krause, A., et al., FEBS Lett. 480: 147-150 (2000). 11. Fleming, R.E. and Sly, W.S., PNAS 99: 8160-8162 (2001). 12. Nicolas, G., et al., PNAS 99: 4596-4601 (2002).